Currently out of the existing stock ratings of Mark Breidenbach, 127 are a BUY (99.22%), 1 are a HOLD (0.78%).

Mark Breidenbach

Work Performance Price Targets & Ratings Chart

Analyst Mark Breidenbach, currently employed carries an average stock price target met ratio of 41.27% that have a potential upside of 50.21% achieved within 204 days.

Mark Breidenbach’s has documented 247 price targets and ratings displayed on 22 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on ALLO, Allogene Therapeutics at 21-May-2024.

Wall Street Analyst Mark Breidenbach

Analyst best performing recommendations are on KDMN (KADMON HOLDINGS).
The best stock recommendation documented was for ARVN (ARVINAS) at 12/14/2020. The price target of $80 was fulfilled within 8 days with a profit of $21.62 (37.03%) receiving and performance score of 46.29.

Average potential price target upside

of $35.48 (75.94%) on MBIO (MUSTANG BIO).
of $32.39 (110.86%) on GBT (GLOBAL BLOOD THERAPEUTICS).
of $15.7 (169.14%) on NRIX (NURIX THERAPEUTICS ).

ALLO Allogene Therapeutics ARVN Arvinas BLUE Bluebird bio CRBU Caribou Biosciences EPIX ESSA Pharma GBT Global Blood Therapeutics GMDA Gamida Cell Ltd IOVA Iovance Biotherapeutics MBIO Mustang Bio MCRB Seres Therapeutics SYBX Synlogic CGEN Compugen FMTX Forma Therapeutics Holdings IMRX Immuneering Corp ALPN Alpine Immune Sciences KDMN Kadmon Holdings SYRS Syros Pharmaceuticals ACHL Achilles Therapeutics PLC ADR CUE Cue Biopharma FTSV Forty Seven NRIX Nurix Therapeutics BLRX BioLineRx Ltd

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Robert Burns (HC WAINWRIGHT)